The first and only FDA-approved treatment for people with early-onset TK2d

KYGEVVI is used for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and children with a symptom onset on or before 12 years of age.

How KYGEVVI works

KYGEVVI is intended to support mitochondrial DNA (mtDNA) production in muscles.

Improved survival time

Studies found that KYGEVVI may help people with early-onset TK2d live longer.

View trial results

Starting KYGEVVI

KYGEVVI is taken 3 times a day orally or by feeding tube.

See dosing info

The Music Box: An early-onset TK2d story

Every person with TK2d experiences their own unique journey to diagnosis and treatment. Watch the journey of a father and his son as they experience the onset of symptoms, search for a diagnosis, and ultimately receive treatment.

Support is available throughout KYGEVVI treatment
With ONWARD®, you and your loved one will receive personalized support throughout your treatment journey with KYGEVVI. You will be assigned your own dedicated Care Coordinator,* who can help review financial assistance options, support you in working with the specialty pharmacy, PANTHERx Rare, and provide tools and resources to get started with, and ongoing support for, treatment with KYGEVVI.

*ONWARD Care Coordinators do not provide medical advice and will refer you to your healthcare professional for any questions related to your treatment plan.

ONWARD is provided as a service of UCB and is intended to support the appropriate use of UCB medicines. ONWARD may be amended or canceled at any time without notice. Some program and eligibility restrictions may apply.

INDICATION

KYGEVVI is a prescription medicine used for the treatment of thymidine kinase 2 deficiency (TK2d) in adults and children with a symptom onset on or before 12 years of age.

IMPORTANT SAFETY INFORMATION

KYGEVVI may cause serious side effects including elevated liver enzyme levels. Increased liver enzyme levels in your blood are common with KYGEVVI. Your healthcare provider will do blood tests to check your liver enzyme levels before starting treatment and during treatment with KYGEVVI.

Tell your healthcare provider right away if you develop any signs or symptoms of liver problems, including loss of appetite, pain on the right side of your stomach area, dark or amber-colored urine, yellowing of your skin or the white part of your eyes, nausea and vomiting, or itching.

KYGEVVI may cause stomach and intestinal (gastrointestinal) problems. Diarrhea and vomiting are common with KYGEVVI, but may also be severe and lead to hospitalization. Tell your healthcare provider right away if you have diarrhea or vomiting during treatment with KYGEVVI that lasts longer than a few days.

The most common side effects of KYGEVVI include diarrhea, stomach area (abdominal) pain including pain in the upper stomach area, vomiting, and increased liver enzyme levels in your blood.

Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with KYGEVVI if you develop certain side effects.

Before taking or giving KYGEVVI, tell your healthcare provider about all of your medical conditions, including if you have or have had liver problems. In addition, tell your healthcare provider if you are pregnant or plan to become pregnant. It is not known if KYGEVVI will harm your unborn baby. Also, tell your healthcare provider if you are breastfeeding or plan to breastfeed. It is not known if KYGEVVI passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take KYGEVVI. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

These are not all of the possible side effects of KYGEVVI. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to UCB, Inc. at UCBCares® (1-844-599-CARE [2273]).

Please see additional information in the Patient Information Leaflet.